Cédric Barra
Senior Investment Manager (Life Sciences) @ OCCIDENT
Cédric Barra is a seed investor at OCCIDENT focused on Health Care and Medical Device. Cédric Barra
- Total investments:
- 10
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Cédric Barra invests in
Stages Cédric Barra invests in
Countries Cédric Barra invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 5 (50%)
- Medical Device 4 (40%)
- Biotechnology 2 (20%)
- Medical 1 (10%)
- Wellness 1 (10%)
Stage
- Seed 2 (20%)
- Series B 2 (20%)
- Series C 2 (20%)
- Series A 1 (10%)
- Series D 1 (10%)
Country
- Switzerland 4 (40%)
- Germany 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Hemotune is a medical device company that develops a therapeutic blood purification platform for treatment of health ailments. | $15.6M / Series B / Mar 25, 2024 | ||
| Lunaphore Technologies S.A. is a Swiss company born with the vision of accelerating cancer research by bringing the field of spatial biology into mainstream laboratories. Lunaphore has developed its innovative spatial biology solutions based on an award-winning technology called FFeX (Fast Fluidic Exchange). Lunaphore has been recognized as one ofthe most innovative companies internationally. | $32.7M / Series D / Mar 23, 2023 | ||
| Avelo mission is to save lives by bringing fast and actionable infectious disease diagnoses to primary care. | $2.3M / Seed / Sep 20, 2022 | ||
| Invasight is a clinical biotech company that focused on revolutionizing cell invasion research. The company was founded in 2019 and is headquartered in Zurich, Switzerland. | $4.6M / Seed / Jun 07, 2022 | ||
| Hemotune is a medical device company that develops a therapeutic blood purification platform for treatment of health ailments. | $7.5M / Series B / Apr 26, 2022 | ||
| Lunaphore Technologies S.A. is a Swiss company born with the vision of accelerating cancer research by bringing the field of spatial biology into mainstream laboratories. Lunaphore has developed its innovative spatial biology solutions based on an award-winning technology called FFeX (Fast Fluidic Exchange). Lunaphore has been recognized as one ofthe most innovative companies internationally. | $12M / Convertible Note / Aug 01, 2021 | ||
| Lunaphore Technologies S.A. is a Swiss company born with the vision of accelerating cancer research by bringing the field of spatial biology into mainstream laboratories. Lunaphore has developed its innovative spatial biology solutions based on an award-winning technology called FFeX (Fast Fluidic Exchange). Lunaphore has been recognized as one ofthe most innovative companies internationally. | $23.6M / Series C / Feb 06, 2020 | ||
| Lunaphore Technologies S.A. is a Swiss company born with the vision of accelerating cancer research by bringing the field of spatial biology into mainstream laboratories. Lunaphore has developed its innovative spatial biology solutions based on an award-winning technology called FFeX (Fast Fluidic Exchange). Lunaphore has been recognized as one ofthe most innovative companies internationally. | $5.5M / Series B / Aug 30, 2018 | ||
| Implandata Ophthalmic Products is an early stage, privately-held, venture capital funded medical device company based in Hannover, Germany. Implandata Ophthalmic Products is a medical device company offering a new technology for the treatment and management of glaucoma patients. It identifies an underserved area in care of glaucoma patients,creating disruptive solutions for better and more efficient glaucoma therapy, to the benefit of glaucoma patients, families, and care givers by integrating innovative medical technology with information technology.IOP has developed a novel technology for 24 hour measurement of intraocular pressure, by which monitoring and therapy of glaucoma patients will be improved. This solution will allow a more efficient treatment and management of glaucoma patients.Implandata Ophthalmic Products was founded on 2010. | Series C / May 14, 2018 | ||
| Lunaphore Technologies S.A. is a Swiss company born with the vision of accelerating cancer research by bringing the field of spatial biology into mainstream laboratories. Lunaphore has developed its innovative spatial biology solutions based on an award-winning technology called FFeX (Fast Fluidic Exchange). Lunaphore has been recognized as one ofthe most innovative companies internationally. | $7M / Series A / Jul 15, 2017 |
Co-Investors
About OCCIDENT
Occident is an international, privately held investment company based in Zug and Munich. Our goal is to manage our own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through our investments. Venture Capital is the focus of our investment activities. We see ourselves as a long-term oriented enabler forinnovative start-ups and visionary founders. As a complementary team of experts, we are fascinated by technologically sound topics (deep tech) from the life sciences, digital and high-tech sectors with the potential to decisively improve people's lives.
OCCIDENT Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Cédric Barra
Senior Investment Manager (Life Sciences)
|
|||
Mirco Müller
Junior Investment Manager (Life Sciences)
|
|||
Paul Sunzenauer
Junior Investment Manager (Life Sciences)
|
|||
Simon Schild von Spannenberg
Investment Manager (Industrial Tech)
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Cédric Barra invest in?
Cédric Barra invests primarily in Health Care, Medical Device and Biotechnology startups, most often at Seed and Series B stage. Most of the 10 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Cédric Barra?
Public channels for Cédric Barra include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Cédric Barra last invest?
The most recent investment recorded for Cédric Barra closed in Mar 2024. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
